تريتايس ٢٫٥ ملغ

main_info

  • trade_name:
  • تريتايس ٢٫٥ ملغ
  • pharmaceutical_form:
  • TABLETS
  • administration_route:
  • PER OS
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic
  • manufactured_by:
  • SANOFI - AVENTIS S.P.A., ITALY

documents

localization

  • country:
  • تريتايس ٢٫٥ ملغ
    إسرائيل
  • language:
  • العربية

therapeutic_information

  • therapeutic_group:
  • ACE INHIBITORS, PLAIN
  • therapeutic_indication:
  • Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction. For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( <0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

status

  • source:
  • Ministry of Health - State of Israel
  • authorization_number:
  • 124603041300
  • authorization_date:
  • 01-01-2012
  • last_update:
  • 09-08-2016